181647-06-3 Usage
Uses
Used in Organic Synthesis:
4-[N-ETHYL-(4-METHOXYPHENYL)METHYLAMINO]-2-BUTYNYL-1-OL is used as a synthetic building block for the creation of more complex organic compounds. Its unique structure allows it to be a versatile component in the synthesis of various molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-[N-ETHYL-(4-METHOXYPHENYL)METHYLAMINO]-2-BUTYNYL-1-OL is used as an intermediate in the development of new drugs. Its specific functional groups and structural features make it a valuable candidate for the synthesis of novel therapeutic agents.
Used in Agrochemical Industry:
4-[N-ETHYL-(4-METHOXYPHENYL)METHYLAMINO]-2-BUTYNYL-1-OL is also utilized in the agrochemical industry for the synthesis of new pesticides and other agricultural chemicals. Its unique properties can contribute to the development of more effective and environmentally friendly products.
Used in Specialty Chemicals:
In the specialty chemicals sector, 4-[N-ETHYL-(4-METHOXYPHENYL)METHYLAMINO]-2-BUTYNYL-1-OL is employed as a key component in the synthesis of various high-value chemicals. Its versatility and unique structure make it an essential building block for the development of innovative materials and products.
Check Digit Verification of cas no
The CAS Registry Mumber 181647-06-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,6,4 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 181647-06:
(8*1)+(7*8)+(6*1)+(5*6)+(4*4)+(3*7)+(2*0)+(1*6)=143
143 % 10 = 3
So 181647-06-3 is a valid CAS Registry Number.
181647-06-3Relevant articles and documents
Treating urinary incontinence using (S)-desethyloxybutynin
-
, (2008/06/13)
A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering a therapeutically effective amount of (S)-oxybutynin, (S)-desethyloxybut